



20th KM Hosur Road, Electronics City, Bangalore 560 100

Bangalore, July 15, 2020

Biocon's Q1 FY 2020-21 Results Conference Call

At 9.00 am IST on July 24, 2020

Biocon Limited (BSE code: 532523, NSE Id: BIOCON) will announce results for the first quarter ended June 30, 2020 on July 23, 2020. Following the announcement, the management of Biocon Limited will host an earnings call to discuss the Company's performance on July 24, 2020.

Details of the conference call are as under:

Date:	Friday, July 24, 2020
Time:	9.00 am IST
Duration:	60 minutes
JOINING INFORMATION	
1. Pre-Registration Facility (Express Join, No Wait Time)	<ul style="list-style-type: none">Step 1: Pre-register here. You will receive an email confirmation with the call details on the registered email addressStep 2: Dial into the call on the Conference Call date, you are directly connected to the call
2. Dial-in Numbers:	
When using dial-in numbers mentioned below please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time. If you reach on operator during the dial in process please inform the operator that you would like to join " Biocon Ltd. Q1 FY21 Earnings Conference Call "	
Universal Access numbers	+91 22 6280 1151 +91 22 7115 8052
Local Access (All India)	+91 70456 71221
International Local Access Numbers	USA: +1 323 386 8721 UK: +44 20 3478 5524 Singapore: +65 3157 5746 Hong Kong: +852 3018 6877 Japan: +81 3 4589 9421
Replay Facility	The replay will be available 60 minutes after the earnings call ends. Dial in number: +91 22 7194 5757, 6663 5757 Playback Code: 56227 Replay available till July 31, 2020
Transcript	Will be made available after a few days on the Company's website

Please note: This call is not open to the members of the media (print/online)

About Biocon

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. www.biocon.com. Follow-us on Twitter: @bioconlimited

Biocon Biologics is a subsidiary of Biocon Ltd. It is uniquely positioned as a fully integrated 'pure play' biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company's portfolio of biosimilar molecules comprises a rich pipeline of approved and in-development biosimilars, which are an outcome of its high end R&D and global scale manufacturing expertise. The Company has commercialized three of its biosimilars in the developed markets like EU, U.S., Japan and Australia. It is a leading global insulins player with over 15 years of experience in addressing the needs of patients with diabetes, having provided over 2 billion doses of human insulin worldwide, thus far. Follow-us on Twitter: @BioconBiologics

Contact:

For further information please contact:

Saurabh Paliwal

Investor Relations – Biocon Limited

☎ +91 80 6775 2040 / 2808 2040

✉: investor.relations@biocon.com

Diwakar Pingle

Christensen Investor Relations

☎ +91 22 4215 0210

✉: dpingle@ChristensenIR.com

Safe Harbor: *Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current assumptions and expectations concerning future developments and their potential effects upon Biocon and its subsidiaries/associates. There can be no assurance that future developments affecting Biocon and its subsidiaries/associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties that may cause actual results to differ, possibly materially, from those contemplated by such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our subsidiaries/ associates assume any obligation to update or otherwise revise any statements reflecting circumstances arising after conclusion of the conference call to reflect the occurrence of underlying events, even if the underlying assumptions and expectations do not come to fruition.*